After AI Finds a Candidate, What Gets Paid For? ↗
Distinguishes drug rights and trial-service fees from collaborative discovery models.
Frozen card revision. This is the recorded reading, not an automatically refreshed view. Current card ↗
R&D Allocation · TOPIC v1
What does an AI business sell when it helps run a clinical trial?
Who pays for the work of making AI-enabled trials viable, and what do they buy?
Read article → What does an AI business sell when it helps run a clinical trial?
2026-10-09 01:41:29.000 UTC · Last recorded update
CURRENT READING
SURPASS calls for validation in real trials, with initial public support and a route to continuing operations. Participation does not establish an automatic allocation of drug development or commercial rights.
Recorded editorial state, not a maturity score
- Reports and agreements reviewedRecorded
- Further validationUnverified
- Adoption and benefitUnverified
New question opened · v1
Examine continuing operations and payment for AI-enabled trials through the SURPASS solicitation.
Permanent link to this revision ↗01 / WHAT WE TRACK
Who pays for the work of making AI-enabled trials viable, and what do they buy?
02 / EVIDENCE & TECHNOLOGY
Platform trials / predictive models / trial-operation automation
03 / EDITORIAL READING
The business question is whether a trial operation covering statistics, site work and regulatory evidence can become a service for the next customer, beyond a software demonstration.
04 / WHAT REMAINS UNKNOWN
A solicitation is not evidence of performance or revenue. Drug rights, model rights and data-use terms must be considered separately; IP terms depend on individual agreements.
05 / NEXT CHECK
Selected teams, trial execution, payment by later sponsors and terms for model and patient-data use.
A hypothesis to keep honest
HYPOTHESIS · NOT YET TESTEDThe ability to deliver a trial through regulatory explanation may support recurring service revenue beyond AI licensing.
What would change our view: Reconsider if customers will not pay after subsidies, trial quality or efficiency does not improve, or reusable contractual terms cannot be established.
A prospective test proposal, not a prediction score. A graph connection does not validate this hypothesis.
Linked people & organizations
Open an entity to find its cardsINSTITUTION / INFRASTRUCTUREARPA-H ↗
Who checks clinical AI decisions, and how is that supervision itself evaluated?
INSTITUTION / INFRASTRUCTURESURPASS ↗
Mentioned in this issue
Related questions, optional follows
Map ↗Who Will Build the Systems to Oversee Clinical AI? ↗
Trial infrastructure and clinical AI oversight are different programmes, compared here through validation and responsibility.
Latest card updates
Latest 5 · editorial record dates- v1 · 2026-10-09 01:41:29.000 UTCNew question opened
Examine continuing operations and payment for AI-enabled trials through the SURPASS solicitation.
Reading at the time: SURPASS calls for validation in real trials, with initial public support and a route to continuing operations. Participation does not establish an automatic allocation of drug development or commercial rights.
Earlier updates (0)
Earlier entries will appear here once more than five reader-facing revisions have accumulated.
Background readings
Source dates and verification scope
SURPASS公式 ↗
arpa-h.gov · · linked-primary-source
公募文書の公開コピー ↗
everglade.com · · solicitation-public-copy
ARPA-Hの契約・応募FAQ ↗
arpa-h.gov · · linked-primary-source